Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices

• Short seller Hunterbrook flagged three new deaths linked to the Dexcom G7 reported in the FDA MAUDE database.
• It stated that at least 13 G7 users have died since the device launched in 2023. 
• This is the second time the firm has published data around Dexcom, after first disclosing its short position in September.

Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor.

DXCM’s stock fell nearly 2%, with retail sentiment on Stocktwits around the company trending in ‘bearish’ territory over the past day.  Hunterbrook first disclosed its short position in September, citing inaccurate G7 readings that allegedly sent patients to ICUs or led to worse outcomes. 

FDA Data Shows Device Risks

The short seller said the new deaths were documented in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which tracks adverse events involving medical devices. It noted that while the reports do not necessarily prove the device caused the deaths, they help regulators and manufacturers flag potential risks.

Hunterbook highlighted that one report described a 69-year-old man whose G7 sensor failed to provide readings, and a second involved a patient using the G7 with an automated insulin pump, whose inaccurate reading may have contributed to fatal ketoacidosis. The third report cited a woman who relied on the G7’s receiver alarms, which had been recalled days earlier for failing to sound properly.

Ongoing Scrutiny And Product Concerns

The short seller stated that at least 13 G7 users have died since the device launched in 2023. It said that even the FDA issued a warning letter to Dexcom in March 2025 following a surprise inspection that revealed unauthorized design changes to a key component, which internal testing found inferior. 

Dexcom reportedly continued selling the device despite these findings. The short seller stated that the resulting controversy has triggered executive departures, insider selling, and patients returning to older G6 devices or switching to competitors, while ongoing lawsuits and regulatory scrutiny weigh on the company.

DXCM’s stock has declined 11% this year and more than 8% since Hunterbrook first disclosed its short position.

Read also: Bitcoin Holds Near $114K Ahead of Fed Rate Decision — SOL, XRP Edge Higher

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on